Jennifer, also known as, “Trie”, is an Associate Director in Medical Affairs for Jazz Pharmaceuticals, leading the Cannabinoid Science Education program. Trie has been working in the cannabinoid science space for nearly 7 years and was instrumental in building the content for CannabinoidClinical.com educational website and leads the Cannabinoid Education Working Group. Trie has presented to learners across the United States including scientific and healthcare providers, advocacy groups, medical societies, state government and policy making members, and beyond the US including the UN Commission on Narcotic Drugs. Prior to her current role, Trie was a Medical Science Liaison at Greenwich Biosciences, US subsidiary of GW Pharmaceuticals, providing scientific support to develop an FDA-approved cannabidiol therapy for the treatment of seizures associated with epilepsy. Trie received her Master of Science in Cellular and Molecular Biology from Saint Cloud State University and her PhD in Comparative and Molecular Biosciences at the University of Minnesota, School of Veterinary Medicine. Before graduate school, she spent several years working in academia performing laboratory research focused on neuroendocrinology.
Once upon a time, a long time ago, in 1990, people were dying of prescription opioids. Those were the 'good ol days" when 100...
Libby Jones is the Program Director of Global Health Advocacy Incubator, GHAI’s Overdose Prevention Initiative. Libby leads the Initiative’s advocacy efforts, advancing federal policies...
Should there be consequences for dealing fentanyl? Should that consequence include secondary murder charges when known counterfeit pills kill people ? State Senator Thomas...